地诺单抗一盒多少钱？

(Xgeva) is an anti-cancer injectable drug primarily used to treat breast cancer. With the advancement of medical technology, the therapeutic potential of denosumab has also been exploited by overseas medical treatments. In addition to being used to treat breast cancer, denosumab is also approved for the prevention of bone-related events in solid tumors with bone metastases and is not used for the prevention of bone-related events in patients with multiple myeloma. It is approved for use in adults or bone-mature adolescents with giant cell tumors of bone that cannot be resected or that may cause serious complications after surgical resection. Approved for hypercalcemia in bisphosphonate-resistant malignancies.

Bone metastasis is one of the most common metastasis sites of cancer and is widely found in many cancer types such as breast cancer, lung cancer, prostate cancer, and uterine cancer. Data show that about 65%-75% of patients with advanced breast cancer will develop bone metastasis, while among patients with lung cancer, this number is about 30%-40%, accounting for more than one-third. In fact, secondary cancer that has metastasized to the bone is difficult to cure, but people can still reduce symptoms and prolong survival with standard treatments.

Denosumab is a better drug for the treatment of bone metastases, which can relieve the pain and related complications caused by bone metastases. Like bisphosphonates, denosumab can reduce complications related to bone metastasis and prevent fractures; unlike bisphosphonates, denosumab targets a different protein receptor. Denosumab has a good therapeutic effect on breast cancer bone metastasis and prostate cancer bone metastasis.

Here comes the question that patients are most concerned about: How much does a box of denosumab cost?

The specification in the United States is 60mg/1ml tube/box, priced at US$1,169.98, which is unaffordable for most patients. Denosumab, which is launched in Turkey, has a specification of 125mg/1ml tube/box and sells for about $3,000, which is the most cost-effective one. At present, denosumab is not yet available in my country.